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Molecul ar Method
Matrix-assisted laser desorption/ionization, time-of-flight mass 
spectrometry (MALDI-TOF MS), is a sensitive analytical method 
capable of resolving DNA fragments varying in mass by a 
single nucleotide. MALDI-TOF MS is applicable to blood group 
genotyping, as the majority of blood group antigens are encoded 
by single nucleotide polymorphisms. Blood group genotyping by 
MALDI-TOF MS can be performed using a panel (Hemo ID Blood 
Group Genotyping Panel, Agena Bioscience Inc., San Diego, CA) 
that is a set of genotyping assays that predict the phenotype for 
101 antigens from 16 blood group systems. These assays involve 
three fundamental stages: multiplex target-specific polymerase 
chain reaction amplification, allele-specific single base primer 
extension, and MALDI-TOFMS analysis using the MassARRAY 
system. MALDI-TOF MS–based genotyping has many advantages 
over alternative methods including high throughput, high 
multiplex capability, flexibility and adaptability, and the high 
level of accuracy based on the direct detection method. Currently 
available platforms for MALDI-TOF MS–based genotyping are 
not without limitations, including high upfront instrumentation 
costs and the number of non-automated steps. The Hemo ID 
Blood Group Genotyping Panel, developed and optimized in a 
collaboration between the vendor and the Blood Transfusion 
Service of the Swiss Red Cross in Zurich, Switzerland, is not 
yet widely utilized, although several laboratories are currently 
evaluating the MassARRAY system for blood group genotyping. 
Based on the accuracy and other advantages offered by MALDI-
TOF MS analysis, in the future, this method is likely to become 
widely adopted for blood group genotyping, in particular, for 
population screening. Immunohematology 2015;31:75–80.
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Matrix-assisted laser desorption/ionization, time-of-flight 
mass spectrometry (MALDI-TOF MS), is a sensitive analytical 
method for the analysis of biomolecules, initially described 
for proteomics analyses in 1988.1,2 Proteomics applications 
of MALDI-TOF MS have greatly diversified and now include 
evaluation of the expression of specific proteins or peptides in 
clinical samples for diagnosis of conditions including cancers, 
ischemic stroke, diabetes, and major depression.3,4 The 
identification of microorganisms based on peptide and protein 
biomarkers is another widely utilized application of MALDI-
TOF MS.5,6 The analysis of nucleic acids by MALDI-TOF MS 
was first described in 1995 when the ability of MALDI-TOF 
MS to resolve DNA fragments varying in mass by a single 
nucleotide was demonstrated by Tang et al.7
Genotyping assays using MALDI-TOF MS can be 
separated into three distinct stages: multiplex target-specific 
polymerase chain reaction (PCR) amplification, allele-specific 
single base primer extension, and MALDI-TOF MS analysis. 
For single base primer extension, primers are designed to 
anneal adjacent to the single nucleotide polymorphism (SNP) 
of interest, and the reaction occurs in the presence of termi-
nating nucleotides (similar to the use of dideoxynucleotides in 
Sanger sequencing) to limit the extension to one nucleotide. 
This generates allele-specific terminated extension products 
of defined mass, dependent on the nucleotide incorporated at 
the polymorphic base. The DNA extension products are then 
analyzed by MALDI-TOF MS. The power of MALDI-TOF 
MS analysis rests in the ability of the platform to resolve the 
intrinsic physical property of the analyte, the molecular mass. 
This principle makes MALDI-TOF MS an excellent tool for 
approaching high-throughput analysis of variants, including 
SNPs, and insertions/deletions, as well as somatic mutation 
screening, quantitative gene expression and copy number 
variation analysis, and DNA methylation detection.8
MALDI-TOF MS is an attractive method for blood group 
genotyping because the majority of blood group antigens are 
encoded by SNPs. The application of MALDI-TOF MS to 
broad red blood cell (RBC) genotyping was first described by 
Gassner et al. at the Blood Transfusion Service of the Swiss 
Red Cross in Zurich, Switzerland, in a large cooperative project 
with Sequenom, Hamburg, Germany (now Agena Bioscience).9 
The aim of this large cooperative project was to develop and 
implement a high-throughput blood group genotyping assay 
utilizing MALDI-TOF MS technology. As an outcome of this 
project, the Hemo ID Blood Group Genotyping Panel (Hemo 
ID Panel) was developed and is now a commercially available 
MassARRAY-based blood group genotyping assay (Agena 
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Bioscience Inc., San Diego, CA). The Hemo ID Panel predicts 
the phenotype of 101 antigens, including RBC antigens from 16 
blood group systems and 23 platelet and neutrophil antigens. 
MALDI-TOF MS has also been validated for blood group 
genotyping of maternal blood samples, for prediction of fetal 
D and K antigen status, although this application is outside the 
scope of this review.10,11
The aim of this review is to describe blood group 
genotyping utilizing MALDI-TOF MS with a focus on the 
methods, strengths, limitations, and implementation of this 
approach.
Materials and Methods
Overview of the Hemo ID Panel
The Hemo ID Panel genotypes 170 alleles to predict 
phenotypes for 101 antigens. The Hemo ID Panel can be 
used in full for comprehensive analysis or separated into 
six modules that can be purchased and run individually for 
targeted genotyping. The modules currently available are 
the Kell, Kidd, and Duffy; MNS; Rare Blood Groups; RHD-
RHCE Broad (RHD/C/E B); RHD Variant; and HPA and HNA 
modules. The variants genotyped in each module are described 
in detail by Gassner et al. and in the Hemo ID Blood Group 
Genotyping Panel User Guide, supplied by Agena Bioscience 
with the purchase of a Hemo ID Panel kit.9,12
The Hemo ID Panel genotyping procedure is described by 
Gassner et al. and detailed step-by-step in the user guide.9,12 The 
Hemo ID Panel kits contain all primers and reagents required 
for genotyping, including nucleotides, buffers, enzymes for 
PCR and post-PCR processing steps, and 96- or 384-well 
plate launching pads (SpectroCHIPs, Agena Bioscience Inc.). 
Genotyping utilizing the full Hemo ID Panel requires 10 
multiplex reactions (wells) per sample, each containing 2 µL of 
genomic DNA (gDNA) at a concentration of 10 ng/µL. In our 
experience, using the 384-well SpectroCHIPs, 33 samples can 
be run in addition to recommended blanks and assay controls.
MassARRAY Genotyping
MassARRAY genotyping can be divided into eight steps. 
Steps 1 to 6 involve analyte preparation and proceed from 
extraction of gDNA to spotting of PCR extension products 
onto a SpectroCHIP; steps 7 and 8 involve analyte analysis 
(Table 1). As with any genotyping method, this procedure 
should be performed in PCR containment facilities to 
minimize risk of contamination from PCR products. The user 
guide details containment recommendations and where each 
procedural step should be conducted.
MassARRAY Genotyping: Analyte Preparation
Step 1 requires isolation of gDNA, from fresh blood or 
tissue, frozen tissue, or cell lines, by standard extraction 
methods. Following isolation of gDNA, a working dilution 
of 10 ng/µL is prepared. Once gDNA samples are prepared, 
MassARRAY genotyping begins with the generation of DNA 
fragments by multiplex target-specific PCR amplification (step 
2). Following generation of DNA fragments, excess nucleotides 
are removed by shrimp alkaline phosphatase (SAP) inactivation 
(step 3) and allele-specific single base primer extension is 
performed (step 4). During the primer extension stage, an 
oligonucleotide primer anneals immediately adjacent to the SNP 
of interest in the presence of the complementary terminating 
nucleotide. This ensures extension is limited to incorporation 
of a single nucleotide complementary to the variant at the SNP 
position. Following this extension, conditioning is performed 
using an ion-exchange resin to remove excess salts that can 
interfere with the quality of the mass spectra (step 5). In step 
6, the DNA extension products (analytes) are dispensed onto 
a SpectroCHIP using the RS1000 Nanodispenser (Agena 
Bioscience Inc.). SpectroCHIPs are pre-spotted with 384 or 96 
spots of matrix; once dispensed, the DNA extension products 
(analytes) and matrix co-crystalize.
MassARRAY Genotyping: Analyte Analysis
In step 7, the SpectroCHIP is inserted into the MassARRAY 
Analyzer for MALDI-TOF MS analysis. During MALDI-TOF 
Table 1. The Hemo ID Panel workflow and required equipment
Step Description Required equipment 
Analyte preparation
1 Obtain gDNA and prepare working 
dilutions 
DNA extraction system; 
spectrophotometer
2 Multiplex PCR using Hemo ID PCR 
primers
Thermal cycler 
3 SAP inactivation Thermal cycler 
4 Extension PCR using Hemo ID 
extension primers
Thermal cycler 
5 Resin conditioning 360° plate rotator





7 MALDI-TOF MS analysis MassARRAY Analyzer 4 
8 Report generation Typer v4.0 software
PCR = polymerase chain reaction; SAP = shrimp alkaline phosphatase; 
MALDI-TOF MS = matrix-assisted laser desorption/ionization, time-of-
flight mass spectrometry. Additional standard laboratory equipment is also 
required, including plate centrifuges, vortex, and microfuge. Genotyping 
should be performed in PCR containment facilities to minimize PCR 
contamination risk.
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MS, the analyte/matrix co-crystals are irradiated with a short 
laser pulse, which causes the matrix and DNA fragments 
to desorb, ionize, and be accelerated in an electric field 
towards a detector. Data acquisition for time of flight (TOF) 
determinations takes 3 to 5 seconds per sample and involves 
20 to 50 laser shots per sample, such that a 384-well plate is 
analyzed within 30 minutes. The TOF is calculated from the 
time of arrival at the detector and is proportional to the mass 
of the individual molecules. Low-mass molecules arrive in a 
shorter time than higher mass molecules, allowing resolution 
of the nucleotide incorporated onto the extension primer at 
the polymorphic site. After data acquisition, a spectrum is 
produced with relative intensity on the y-axis and mass/
charge on the x-axis. An example of the spectrum acquired 
for genotyping of the alleles associated with the Diego blood 
group antigens, Dia and Dib, is shown in Figure 1.
MassARRAY Genotyping: Software and Report 
Generation
When setting up a plate for analysis, the user assigns samples 
and Hemo ID Panel modules to plate wells using software (Typer, 
Agena Bioscience Inc.). The modules are defined by the Hemo 
ID Module Definition Files (available for download), which 
provide all necessary specifications to the software, including 
extension primer sequences and mass, as well as the expected 
products and mass. Acquired data are processed by Hemo ID 
Report software, which analyzes the allele peak intensities to 
determine genotyping calls. The software interprets one, or a 
combination of multiple, genotyping calls to predict phenotype. 
A report is then generated detailing genotype and the associated 
predicted phenotype (step 8). In addition to data acquisition 
and analysis, the Hemo ID Report software includes quality-
control monitoring and allows for extensive customization 
of reports.
Strengths and Limitations
Strengths of MassARRAY Genotyping
MassARRAY-based genotyping has many strengths, 
ranging from the properties of MALDI-TOF MS technology, 
to throughput and flexibility. First, MALDI-TOF MS results 
are determined based on the detection of an intrinsic physical 
property—the molecular mass of the analyte. This differs from 
alternative SNP genotyping methods that rely on differential 
hybridization to allele-specific probes and indirect methods 
such as fluorescence detection to determine genotype. For 
example, indirect genotyping methods often detect either 
a “red” or “green” fluorescent signal, which is correlated to 
the presence or absence of an allele to determine genotype. 
MALDI-TOF MS offers increased accuracy and specificity 
over indirect methods, as genotypes are determined directly 
by detection of a peak at the known mass of an allele; there is 
no requirement for labelling of extension products. Although 
available indirect methods have proved to be robust and are 
widely used, the potential for false negatives or false positives is 
higher than for MALDI-TOF MS–based genotyping.8,13–15 The 
robustness of the MassARRAY platform and Hemo ID Panel 
have been demonstrated by Sequenom and independently by 
Meyer et al. with interlaboratory reproducibility studies.16,17 
Sequenom reported a rate of 100 percent concordance 
between genotype and phenotype for 47 samples across three 
collaborating laboratories. In the study by Meyer et al., 760 
Fig. 1. Matrix-assisted laser desorption/ionization, time-of-flight 
mass spectrometry (MALDI-TOF MS) mass spectra plotting peak 
intensity (y-axis) against mass (daltons) (x-axis). MassARRAY Typer 
software analyzes the allele peak intensities to determine genotype 
calls. The example mass spectra here are taken from an assay 
genotyping the Diego blood group alleles DI*A and DI*B. (A) Mass 
spectrum of a DI*B/B sample showing a single peak of 5169 Da 
indicating homozygosity for cytosine. (B) Mass spectrum of a DI*A/A 
sample showing a single peak at 5249 Da indicating homozygosity 
for thiamine. (C) Mass spectrum of a DI*A/B sample showing peaks 
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samples were tested in two collaborating laboratories for a total 
of 11,400 SNPS with resulting genotype call rates differing by 
only 0.5 percentage points between the two laboratories (99% 
and 98.5% call rates), and the genotyping concordance was 
100 percent.17 
The optimal application of MALDI-TOF MS–based 
genotyping is high-throughput, as the technology supports 
very highly multiplexed reactions. MALDI-TOF MS assays 
are robust up to the 40× multiplex level.18 In principle, the 
MassARRAY system has the capacity to genotype over 
100,000 SNPs per day. For blood group genotyping, Meyer 
et al. reported that one technician could genotype 760 gDNA 
samples with the Hemo ID Kell, Kidd, and Duffy module 
(which genotypes 15 SNPs) in 8 hours with 2.5 hours of hands-
on time, excluding gDNA extraction and data processing.17
Finally, the MassARRAY system with the Hemo ID Panel 
offers adaptability and flexibility, as genotyping is based on 
the principle of single base extension. This means assays can 
be easily adapted by adding/removing PCR and extension 
primers, as no fixed format DNA chips are required. For 
example, when the genetic basis of the Vel blood group antigen 
was described in 2013,19 the associated polymorphism was 
incorporated into the Hemo ID Panel by the manufacturer 
within 4 weeks. The Hemo ID Panel also offers flexibility, 
as the multiple genotyping modules can be purchased 
and run as a comprehensive genotyping assay, or tested 
individually to allow targeted genotyping. If further flexibility 
or customization is desired, design of custom MassARRAY 
assays is a straightforward process. Custom design of assays 
is performed with the online MassARRAY Assay Design 
Suite (ADS) software (https://www.agenacx.com) and 
involves the input of polymorphisms of interest, followed by 
the automatic generation of PCR and extension primers and 
multiplex reactions. Following custom design, kits containing 
all required primers and reagents for MassARRAY genotyping 
are available from Agena Bioscience.
Limitations of MassARRAY Genotyping
MALDI-TOF MS genotyping has some limitations, 
including high upfront instrument acquisition costs and 
the number of non-automated steps. First, the cost of 
instrumentation required for MassARRAY genotyping 
is relatively high in comparison with other commercially 
available genotyping systems. MassARRAY genotyping 
requires equipment standard to most laboratories, including 
thermocylers and plate centrifuges, in addition to two 
specialized pieces of equipment: a nanodispenser and 
mass spectrometer (Table 1). The list price for the complete 
MassARRAY 4, 384-well format system is ~$295,000, and a 
96-well format system costs ~$200,000. All figures provided 
are in U.S. dollars and are current as of September 2015. Once 
instrumentation has been purchased, the cost of genotyping 
on the MassARRAY system is comparable to or less expensive 
than, other methods. Per-sample cost for analysis on the 
complete Hemo ID Panel would cost ~$110 in consumables on 
the 384-well format system, or ~$135 on the 96-well format 
system. Considering the complete Hemo ID panel provides 
predicted phenotypes for 101 antigens, this calculates to less 
than $1.35 per antigen, regardless of the format utilized. 
As discussed, the MassARRAY system has high-
throughput genotyping capacity. In combination with the high 
upfront equipment costs, this may be considered a limitation 
by small-sized laboratories, as the cost-to-benefit ratio of low-
throughput testing only, such as referred patient samples, may 
be difficult to justify.
A further limitation is the number of hands-on steps 
involved in the MassARRAY genotyping workflow. Hands-
on steps include the preparation and pipetting of mastermixes 
for the PCR steps (steps 2 and 4), preparation and pipetting 
of the SAP inactivation mastermix (step 3), and the addition 
of resin to reaction wells (step 5). In general, workflows with 
multiple hands-on steps have the potential to introduce human 
error—for example, by incorrectly calculating the quantity of 
mastermix components, or by missing wells during pipetting.20 
Additionally, workflows with multiple hands-on steps reduce 
the reproducibility of assays and increase the risk of amplicon 
contamination. Most of these steps are amenable to liquid 
handling robotics available from Agena Bioscience, but this is 
an additional expense.
Furthermore, the MassARRAY system and the Hemo ID 
Panel, at the time of writing, are not cleared by any regulatory 
body and are therefore for research use only, which may be 
considered a limitation in comparison with longer-established 
systems (BloodChip Reference Progenika Biopharma S.A., 
Grifols, Bizkaia, Spain), which has obtained CE marking, or 
the recently U.S. Food and Drug Administration–approved 
human erythrocyte antigen typing system (PreciseType™ 
HEA Molecular BeadChip™ Test, Bioarray Solutions, 
Immucor, Warren, NJ).
Implementation
The Hemo ID Panel has only recently been developed 
and is not yet widely utilized. As mentioned, this assay was 
developed and validated in part by Gassner et al. at the 
Blood Transfusion Service of the Swiss Red Cross in Zurich, 
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Switzerland.9 Gassner et al. validated the Hemo ID Panel by 
comparing genotype with available phenotype data, including 
samples with known variants.9 The Blood Transfusion Service 
of the Swiss Red Cross has now implemented large-scale 
testing using the Hemo ID Panel with several aims, including 
the genotyping of 36,000 Swiss donors using  the Rare 
Blood Groups module.9,17 The most recent report from this 
laboratory described the genotyping of 4000 samples using 
the Kell, Kidd, and Duffy modules with over 99.7 percent 
genotype/phenotype concordance overall for the clinically 
significant blood group antigens K/k, Kpa/b, Jka/b, and Fya/b.17 
The majority of discrepancies were caused by erroneous 
serology profiles attributable  to weakly expressed antigens, 
with additional discrepancies caused by the presence of rare 
or novel null alleles within the sample set.17 Based on their 
experience to date, Meyer et al. concluded that MALDI-TOF 
MS–based genotyping proved practical in a routine laboratory 
setting and qualitatively outperformed serology.17
At the Australian Red Cross Blood Service, our experience 
with MassARRAY genotyping has been in relation to typing 
reagent RBC donors and other selected donors. We first 
compared the performance of the Hemo ID Panel with two 
established genotyping platforms (BloodChip Reference, 
Progenika, and HEA and RHD BeadChip, BioArray Solutions). 
This involved genotyping of 300 extensively phenotyped 
reagent RBC donors. A phenotype genotype discrepancy rate 
of 7.0 percent was detected, and all discrepancies identified 
were in clinically significant blood group systems.21 In all 
cases of discrepancy, homozygosity for either D, Fya, or Fyb 
was inferred based on serology, but genotyping revealed 
variants encoding weak or null antigen expression.21 Overall, 
this study highlighted the utility of genotyping, specifically for 
identifying donors carrying SNPs associated with weak and 
null antigen expression, which routine serology did not detect. 
Furthermore, in this study, genotyping by all three platforms 
achieved sensitivity and specificity of 100 percent on the 
sample set tested, providing evidence that the MassARRAY 
system and the Hemo ID Panel are equally accurate when 
compared with the established genotyping systems.21
In subsequent studies, the flexibility offered by the 
MassARRAY genotyping platform was explored. These studies 
were undertaken in collaboration with Agena Bioscience to 
develop custom-designed assays for genotyping of certain 
ethnically associated blood group polymorphisms. For all 
of these pilot genotyping studies, MassARRAY genotyping 
data were compared with historical serology and in-house 
genotyping results. When further analysis was necessary, 
samples were tested by Sanger sequencing.
First, we designed and validated a MassARRAY-based 
assay to genotype the SNP associated with Ina and Inb, as 
antisera for phenotyping these antigens are extremely limited.22 
In addition, currently available commercial platforms have not 
incorporated this blood group polymorphism into their tests. 
For 151 samples, the MassARRAY results were 100 percent 
concordant with in-house genotyping and serologic testing 
results, illustrating the potential to extend and develop this 
method for other antigens.22
Second, we designed a MassARRAY-based assay for 
genotyping the SNP 2561C>T of SLC4A1, associated with 
the Diego blood group antigens, Dia and Dib (Figure 1). It is 
important to note that adjacent to the DI*A/B polymorphism 
is a silent SNP, c.2562G>A. Our laboratory has an established 
high-resolution melt analysis assay for genotyping of DI*A/B, 
and this adjacent SNP has the potential to confound genotyping 
results. We included an additional extension primer in our 
DI*A/B MassARRAY assay to allow genotyping of c.2562G>A 
as proof-of-principle to explore the application of genotyping 
multiple SNPs within a single amplicon. We incorporated 
inosine in the extension primer design, as inosine displays some 
bias in base pairing, but is less destabilizing than mismatches 
involving the four standard bases (A/C/G/T). This allowed 
the extension primer to span position c.2561, regardless of 
the DI*A/B genotype, to genotype the SNP at position c.2562. 
This investigation highlights the complexity of genotyping 
and the requirement to reference SNP databases during assay 
design to ensure all reported variants are considered. In 
this case, a MassARRAY assay that overcame this difficulty 
was developed, and MassARRAY results were 100 percent 
concordant with in-house genotyping and serological testing 
results for 151 samples.
Although the majority of blood group antigens are encoded 
by SNPs, two clinically significant blood group systems, Rh 
and MNS, include numerous hybrid alleles. The MassARRAY 
platform uses exon scanning to characterize hybrid alleles 
within the Hemo ID Panel, particularly for the Rh blood group 
system. Our third custom assay focused on genotyping hybrid 
glycophorins within the MNS blood group system, which are 
of interest in the ethnically diverse Australian population. For 
the complex MNS hybrid glycophorins, a genotyping assay 
was developed to classify published GYP(B-A-B) hybrid alleles, 
including the recently characterized GYP*KIP.23
At present, MassARRAY-based genotyping for blood 
group polymorphisms has only been reported by Gassner et 
al. and Meyer et al. from the Blood Transfusion Service of the 
Swiss Red Cross and McBean et al. and Lopez et al. at the 
Australian Red Cross Blood Service.9,17,21,22 In the International 
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Society for Blood Transfusion (ISBT) Molecular Blood Group 
Genotyping Workshop in 2014, four laboratories reported 
using a MALDI-TOF MS–based genotyping platform, and we 
anticipate that future data from these trials will provide further 
evidence of the strengths and limitations of the MALDI-TOF 
MS approach.
In conclusion, MALDI-TOF MS technology offers many 
advantages, including the high level of accuracy based on the 
direct detection of an intrinsic physical property of the analyte, 
high-throughput, high-multiplex capacity, and potential for 
flexibility and adaptation. In the future, MALDI-TOF MS–
based genotyping has the potential to become widely adopted, 
in particular for donor screening for an extended array of blood 
group polymorphisms.
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